Pharsight

Cysview Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10556010 PHOTOCURE ASA Neoadjuvant therapy for bladder cancer
Dec, 2036

(12 years from now)

US11311620 PHOTOCURE ASA Neoadjuvant therapy for bladder cancer
Dec, 2036

(12 years from now)

US11235168 PHOTOCURE ASA Method of photodynamic therapy (PDT) for bladder cancer
Jan, 2038

(13 years from now)

Cysview Kit is owned by Photocure Asa.

Cysview Kit contains Hexaminolevulinate Hydrochloride.

Cysview Kit has a total of 3 drug patents out of which 0 drug patents have expired.

Cysview Kit was authorised for market use on 28 May, 2010.

Cysview Kit is available in for solution;intravesical dosage forms.

Cysview Kit can be used as detection of carcinoma in the bladder by photodynamic cystoscopy.

The generics of Cysview Kit are possible to be released after 04 January, 2038.

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2010

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

More Information on Dosage

CYSVIEW KIT family patents

Family Patents